

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	210121.609USPC	10/550,797
	APPLICANTS Barbara K. Zehentner-Wilkinson et al.	
	FILING DATE	GROUP ART UNIT
	July 26, 2006	1637

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,210,883	04/03/01	Reed et al.	435	6	
	AB	6,426,072	07/30/02	Wang et al.	424	184.1	
	AC	6,509,448	01/21/03	Wang et al.	530	387.9	
	AD	2003/0103994	06/05/03	Watanabe et al.	424	185.1	
	AE						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AF	WO 99/47647	09/23/99	WIPO		
	AG	WO 00/61612	10/19/00	WIPO		
	AH	WO 01/72295	10/04/01	WIPO		
	AI	WO 01/92525	12/06/01	WIPO		
	AJ	WO 02/00174	01/03/02	WIPO		
	AK	WO 02/47534	06/20/02	WIPO		
	AL	WO 02/092001	11/21/02	WIPO		

OTHER ART (Including author, Title, Date, Portion of Pages, Etc.)

	AM	Bangur, C.S. et al., "Identification of genes over-expressed in small cell lung carcinoma using suppression subtractive hybridization and cDNA microarray expression analysis," <i>Oncogene 21</i> : 3814-3825, 2002.
	AN	Genseq Database, Accession No. ABX76178, April 2, 2003.
	AO	Gruber, A.D. et al., "Molecular cloning and transmembrane structure of hCLCA2 from human lung, trachea, and mammary gland," <i>American Journal of Physiology</i> 276: C1261-1270, 1999.
	AP	Konopitzky, R. et al., "Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the Novel Overexpressed Tumor Antigen Calcium-Activated Chloride Channel 2," <i>The Journal of Immunology</i> 169: 540-547, 2002.

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	210121.609USPC	10/550,797
	APPLICANTS Barbara K. Zehentner-Wilkinson et al.	
	FILING DATE	GROUP ART UNIT
	July 26, 2006	1637

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
BB					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

BC	Pentimalli, F. et al., "Suppression of HMGA2 Protein Synthesis Could Be a Tool for the Therapy of Well Differentiated Liposarcomas Overexpressing <i>HMGA2</i> ," <i>Cancer Research</i> 63: 7423-7427, November 1, 2003.
BD	Tessari, M.A. et al., "Transcriptional Activation of the Cyclin A Gene by the Architectural Transcription Factor HMGA2," <i>Molecular and Cellular Biology</i> 23(24): 9104-9116, December 2003.
BE	Wang, T. et al., "Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis," <i>Oncogene</i> 19: 1519-1528, 2000.
BF	Wang, K-k. et al., "Novel candidate tumor marker genes fro lung andocarcinoma," <i>Oncogene</i> 21: 7598-7604, 2002.
BH	
BH	
BH	
BJ	
BK	
BL	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial of reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).